Analysis of the clinical application of ceftazidime-avibactam in China
Background: The efficacy and safety of ceftazidime-avibactam were mainly reported in phase II and phase III clinical trials, rarely in the real-world study. The limited real-world study which evaluated the clinical response of this drug shown inconsistent results. This study aimed to investigate the...
Main Authors: | Qing Wang, Ping Xu, Yangang Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-04-01
|
Series: | Journal of Infection and Public Health |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034122000375 |
Similar Items
-
Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
by: Maria Di Pietrantonio, et al.
Published: (2022-02-01) -
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program
by: Peiyao Jia, et al.
Published: (2022-10-01) -
Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
by: Adnan Alatoom, et al.
Published: (2017-09-01) -
Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study
by: Hai-Hui Zhuang, et al.
Published: (2023-06-01) -
Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection
by: Shuang Xiao, et al.
Published: (2023-08-01)